TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Syntara Limited ( (AU:SNT) ) is now available.
Syntara Limited has received a positive opinion from the European Medicines Agency for Orphan Drug Designation of its clinical asset amsulostat for the treatment of myelofibrosis, a bone marrow disorder. This designation offers several incentives, including market exclusivity and fee reductions, enhancing Syntara’s position in the EU market. Amsulostat has already shown promising results in Phase 2a trials, with significant symptom reduction and excellent tolerability, and has received similar designation in the US. The company is advancing its clinical trials and engaging with regulatory authorities to further develop amsulostat as a differentiated therapy for myelofibrosis.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is a clinical-stage drug development company specializing in targeting extracellular matrix dysfunction. With expertise in amine oxidase chemistry, Syntara develops novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company is listed on the Australian Securities Exchange and is based in Sydney, Australia.
Average Trading Volume: 2,821,819
Technical Sentiment Signal: Sell
Current Market Cap: A$48.97M
For detailed information about SNT stock, go to TipRanks’ Stock Analysis page.